Dashboard
Manage Tickers

RVMD


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-revolution-medicines-maintains-56-price-target
HC Wainwright & Co. Reiterates Buy on Revo...
08/12/2024 11:32:26

HC Wainwright & Co. analyst Robert Burns reiterates Revolution Medicines (NASDAQ:RVMD) with a Buy and maintains $56 pric...

jp-morgan-maintains-overweight-on-revolution-medicines-lowers-price-target-to-54
JP Morgan Maintains Overweight on Revoluti...
08/08/2024 16:25:57

JP Morgan analyst Eric Joseph maintains Revolution Medicines (NASDAQ:RVMD) with a Overweight and lowers the price target fro...

wedbush-reiterates-outperform-on-revolution-medicines-maintains-59-price-target
Wedbush Reiterates Outperform on Revolutio...
08/08/2024 13:16:12

Wedbush analyst Robert Driscoll reiterates Revolution Medicines (NASDAQ:RVMD) with a Outperform and maintains $59 price target.

needham-maintains-buy-on-revolution-medicines-lowers-price-target-to-61
Needham Maintains Buy on Revolution Medici...
08/08/2024 09:58:21

Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and lowers the price target from $62 to $61.

revolution-medicines-q2-2024-gaap-eps-081-misses-077-estimate
Revolution Medicines Q2 2024 GAAP EPS $(0....
08/07/2024 21:25:25

Revolution Medicines (NASDAQ:RVMD) reported quarterly losses of $(0.81) per share which missed the analyst consensus estimate o...

barclays-maintains-overweight-on-revolution-medicines-raises-price-target-to-54
Barclays Maintains Overweight on Revolutio...
07/18/2024 15:38:39

Barclays analyst Peter Lawson maintains Revolution Medicines (NASDAQ:RVMD) with a Overweight and raises the price target fro...

oppenheimer-maintains-outperform-on-revolution-medicines-raises-price-target-to-55
Oppenheimer Maintains Outperform on Revolu...
07/16/2024 12:47:17

Oppenheimer analyst Jay Olson maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target fro...

b-of-a-securities-maintains-buy-on-revolution-medicines-raises-price-target-to-55
B of A Securities Maintains Buy on Revolut...
07/16/2024 12:38:58

B of A Securities analyst Alec Stranahan maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target...

top-3-health-care-stocks-that-should-keep-you-up-at-night-this-quarter
Top 3 Health Care Stocks That Should Keep ...
07/16/2024 12:16:01

microsoft-to-rally-around-6-here-are-10-top-analyst-forecasts-for-tuesday
Microsoft To Rally Around 6%? Here Are 10 ...
07/16/2024 12:05:43

hc-wainwright--co-maintains-buy-on-revolution-medicines-raises-price-target-to-56
HC Wainwright & Co. Maintains Buy on Revol...
07/16/2024 11:50:00

HC Wainwright & Co. analyst Robert Burns maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price ta...

needham-maintains-buy-on-revolution-medicines-raises-price-target-to-62
Needham Maintains Buy on Revolution Medici...
07/16/2024 11:28:10

Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $46 to $62.

barclays-initiates-coverage-on-revolution-medicines-with-overweight-rating-announces-price-target-of-52
Barclays Initiates Coverage On Revolution ...
07/12/2024 12:33:22

Barclays analyst Peter Lawson initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Overweight rating and announce...

revolution-medicines-announces-publication-in-cancer-discovery-demonstrating-robust-anti-tumor-activity-of-rason-inhibitors-in-preclinical-models-of-refractory-kras-mutated-non-small-cell-lung-cancer
Revolution Medicines Announces Publication...
07/11/2024 16:07:24

Original research published in Cancer Discovery reveals a RAS(ON) multi-selective inhibitor exhibited robust anti-tumor activit...

why-helen-of-troy-shares-are-trading-lower-by-around-30-here-are-other-stocks-moving-in-tuesdays-mid-day-session
Why Helen of Troy Shares Are Trading Lower...
07/09/2024 16:59:31

nvidia-micron-arlo-technologies-and-other-big-stocks-moving-higher-on-tuesday
Nvidia, Micron, Arlo Technologies And Othe...
07/09/2024 14:05:05

revolution-medicines-to-provide-update-on-rmc-6236-pancreatic-ductal-adenocarcinoma-clinical-program-on-july-15-2024-in-investor-webcast
Revolution Medicines To Provide Update On ...
07/08/2024 20:09:11

Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS...

jefferies-initiates-coverage-on-revolution-medicines-with-buy-rating-announces-price-target-of-63
Jefferies Initiates Coverage On Revolution...
07/08/2024 12:59:57

Jefferies initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Buy rating and announces Price Target of $63.

hc-wainwright--co-reiterates-buy-on-revolution-medicines-maintains-44-price-target
HC Wainwright & Co. Reiterates Buy on Revo...
05/13/2024 10:33:17

HC Wainwright & Co. analyst Robert Burns reiterates Revolution Medicines (NASDAQ:RVMD) with a Buy and maintains $44 pric...

wedbush-maintains-outperform-on-revolution-medicines-raises-price-target-to-46
Wedbush Maintains Outperform on Revolution...
05/09/2024 12:47:33

Wedbush analyst Robert Driscoll maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target f...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION